Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Space Flight | 12 | 2019 | 170 | 0.910 |
Why?
|
| Weightlessness | 8 | 2019 | 80 | 0.770 |
Why?
|
| Astronauts | 7 | 2019 | 76 | 0.730 |
Why?
|
| Aerospace Medicine | 6 | 2008 | 39 | 0.610 |
Why?
|
| Radiation-Protective Agents | 3 | 2011 | 19 | 0.420 |
Why?
|
| Extraterrestrial Environment | 3 | 2007 | 8 | 0.340 |
Why?
|
| Medullary Sponge Kidney | 1 | 2008 | 2 | 0.290 |
Why?
|
| Radiation, Ionizing | 2 | 2007 | 42 | 0.280 |
Why?
|
| Linear Energy Transfer | 2 | 2007 | 9 | 0.280 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 18 | 0.270 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 23 | 0.270 |
Why?
|
| Gamma Rays | 1 | 2007 | 42 | 0.270 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 87 | 0.250 |
Why?
|
| Military Personnel | 1 | 2008 | 203 | 0.240 |
Why?
|
| Urogenital System | 1 | 2005 | 35 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 392 | 0.230 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 207 | 0.230 |
Why?
|
| Urinary Calculi | 2 | 2008 | 19 | 0.230 |
Why?
|
| Reproduction | 1 | 2005 | 226 | 0.210 |
Why?
|
| Gravitation | 2 | 2000 | 13 | 0.200 |
Why?
|
| Epithelial Cells | 1 | 2007 | 903 | 0.190 |
Why?
|
| Neck Pain | 1 | 2000 | 19 | 0.160 |
Why?
|
| Aircraft | 1 | 2000 | 22 | 0.160 |
Why?
|
| Cervical Vertebrae | 1 | 2000 | 118 | 0.150 |
Why?
|
| Ecological Systems, Closed | 2 | 2008 | 2 | 0.140 |
Why?
|
| Space Simulation | 2 | 2007 | 4 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2019 | 184 | 0.130 |
Why?
|
| Endoscopy | 1 | 1999 | 281 | 0.130 |
Why?
|
| Bone Density | 1 | 2019 | 369 | 0.130 |
Why?
|
| Dogs | 2 | 2007 | 655 | 0.120 |
Why?
|
| Telemedicine | 1 | 1999 | 506 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2006 | 1347 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 1992 | 36 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 60 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 176 | 0.080 |
Why?
|
| Weightlessness Countermeasures | 2 | 2008 | 6 | 0.080 |
Why?
|
| Musculoskeletal System | 1 | 2009 | 19 | 0.080 |
Why?
|
| Rhabdomyosarcoma | 1 | 1992 | 214 | 0.070 |
Why?
|
| Life Support Systems | 1 | 2008 | 5 | 0.070 |
Why?
|
| Antioxidants | 1 | 2011 | 335 | 0.070 |
Why?
|
| Kidney Medulla | 1 | 2008 | 19 | 0.070 |
Why?
|
| Taxoids | 2 | 2006 | 71 | 0.070 |
Why?
|
| Prednisone | 2 | 2006 | 252 | 0.070 |
Why?
|
| Cystostomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Kidney Calculi | 1 | 2008 | 49 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 68 | 0.070 |
Why?
|
| Geography | 1 | 2007 | 124 | 0.070 |
Why?
|
| Horses | 1 | 2007 | 104 | 0.070 |
Why?
|
| Antigens | 1 | 2007 | 149 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 867 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 93 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 53 | 0.060 |
Why?
|
| Sus scrofa | 1 | 2007 | 123 | 0.060 |
Why?
|
| Sheep | 1 | 2007 | 229 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2007 | 146 | 0.060 |
Why?
|
| Thoracic Injuries | 1 | 2007 | 90 | 0.060 |
Why?
|
| Immune System | 1 | 2007 | 97 | 0.060 |
Why?
|
| Animals | 5 | 2011 | 34989 | 0.060 |
Why?
|
| Abdomen | 1 | 2007 | 135 | 0.060 |
Why?
|
| Cell Death | 1 | 2007 | 243 | 0.060 |
Why?
|
| Calcinosis | 1 | 2008 | 191 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 1577 | 0.060 |
Why?
|
| Rabbits | 1 | 2007 | 688 | 0.060 |
Why?
|
| Humans | 25 | 2019 | 132336 | 0.060 |
Why?
|
| Cattle | 1 | 2007 | 576 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 99 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 117 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 45 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2005 | 76 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 388 | 0.060 |
Why?
|
| Estramustine | 1 | 2004 | 4 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 272 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2005 | 34 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2008 | 288 | 0.060 |
Why?
|
| Male | 14 | 2019 | 65054 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2004 | 76 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 591 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 514 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1176 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2007 | 988 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2004 | 55 | 0.050 |
Why?
|
| Swine | 1 | 2007 | 1197 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 392 | 0.050 |
Why?
|
| United States | 5 | 2009 | 11628 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2007 | 800 | 0.050 |
Why?
|
| Motion Sickness | 1 | 2002 | 10 | 0.050 |
Why?
|
| Equipment Design | 2 | 2004 | 605 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2002 | 93 | 0.050 |
Why?
|
| Testicular Neoplasms | 2 | 1995 | 131 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2005 | 317 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2001 | 73 | 0.040 |
Why?
|
| Lens, Crystalline | 1 | 2001 | 110 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2005 | 517 | 0.040 |
Why?
|
| Rats | 1 | 2007 | 3619 | 0.040 |
Why?
|
| Biomarkers | 2 | 2007 | 3389 | 0.040 |
Why?
|
| Weight Lifting | 1 | 2000 | 5 | 0.040 |
Why?
|
| Cataract | 1 | 2001 | 169 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3853 | 0.040 |
Why?
|
| Intervertebral Disc | 1 | 2000 | 14 | 0.040 |
Why?
|
| Head Movements | 1 | 2000 | 27 | 0.040 |
Why?
|
| Ergonomics | 1 | 2000 | 24 | 0.040 |
Why?
|
| Spinal Diseases | 1 | 2000 | 46 | 0.040 |
Why?
|
| Alendronate | 1 | 2019 | 21 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 826 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 174 | 0.040 |
Why?
|
| Posture | 1 | 2000 | 141 | 0.040 |
Why?
|
| Exercise | 2 | 2009 | 865 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 58 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 205 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 138 | 0.040 |
Why?
|
| United States National Aeronautics and Space Administration | 2 | 2008 | 20 | 0.030 |
Why?
|
| Radiation Protection | 2 | 2008 | 58 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1683 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 1018 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 301 | 0.030 |
Why?
|
| Space Suits | 2 | 2007 | 3 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 539 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2006 | 27 | 0.030 |
Why?
|
| Image Cytometry | 1 | 1995 | 11 | 0.030 |
Why?
|
| Adult | 5 | 2019 | 31618 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2683 | 0.030 |
Why?
|
| Mice | 2 | 2011 | 18571 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 296 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1993 | 19 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1993 | 44 | 0.030 |
Why?
|
| Prostatitis | 1 | 1993 | 16 | 0.030 |
Why?
|
| Prevalence | 1 | 2000 | 2665 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1993 | 117 | 0.020 |
Why?
|
| Risk Factors | 3 | 2007 | 10910 | 0.020 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 5405 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2006 | 1570 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Androgens | 1 | 1993 | 277 | 0.020 |
Why?
|
| Female | 6 | 2011 | 70788 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 3744 | 0.020 |
Why?
|
| Ejaculation | 1 | 1990 | 22 | 0.020 |
Why?
|
| Prostate | 1 | 1993 | 437 | 0.020 |
Why?
|
| Middle Aged | 5 | 2019 | 28888 | 0.020 |
Why?
|
| Time Factors | 3 | 2007 | 6455 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1990 | 32 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 203 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 410 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 459 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1990 | 97 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 171 | 0.020 |
Why?
|
| Back Injuries | 1 | 2009 | 4 | 0.020 |
Why?
|
| Foot Injuries | 1 | 2009 | 9 | 0.020 |
Why?
|
| Health Facility Planning | 1 | 2008 | 3 | 0.020 |
Why?
|
| Time | 1 | 2008 | 100 | 0.020 |
Why?
|
| Extravehicular Activity | 1 | 2007 | 3 | 0.020 |
Why?
|
| Facility Design and Construction | 1 | 2007 | 5 | 0.020 |
Why?
|
| Arctic Regions | 1 | 2007 | 4 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2006 | 17363 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 482 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2007 | 35 | 0.020 |
Why?
|
| Virus Latency | 1 | 2007 | 63 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 119 | 0.020 |
Why?
|
| Aged | 5 | 2006 | 21379 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 216 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 344 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2007 | 235 | 0.020 |
Why?
|
| Internationality | 1 | 2007 | 133 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 343 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 210 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 3062 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 492 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 311 | 0.010 |
Why?
|
| Viral Load | 1 | 2007 | 410 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2007 | 261 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 273 | 0.010 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2004 | 7 | 0.010 |
Why?
|
| Nail Diseases | 1 | 2004 | 15 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 449 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 675 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 803 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 503 | 0.010 |
Why?
|
| Diet | 1 | 2011 | 1173 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 7111 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 569 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 137 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 1451 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2002 | 21 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1153 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1992 | 1829 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4767 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1368 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3361 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 308 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1247 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2001 | 139 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 457 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2303 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 237 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 3022 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 816 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2001 | 186 | 0.010 |
Why?
|
| Cisplatin | 1 | 2001 | 281 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1759 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 3710 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1502 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1297 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1989 | 3139 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 14853 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 2187 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 764 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 2151 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 744 | 0.010 |
Why?
|
| Adrenergic Fibers | 1 | 1990 | 4 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1990 | 18 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 1367 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1990 | 61 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1989 | 15 | 0.000 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1989 | 9 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1990 | 443 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1989 | 194 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1989 | 105 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1989 | 560 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2001 | 13016 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1993 | 4725 | 0.000 |
Why?
|